Construction and Clinical Significance of Prognostic Risk Markers Based on Cancer Driver Genes in Lung Adenocarcinoma

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2024 Sep 18

PMID 39292390

Authors

Yazhou Su

Tingting Huo

Yanan Wang

Jingyan Li

Affiliations

Soon will be listed here.

Abstract

Background: Cancer driver genes (CDGs) have been reported as key factors influencing the progression of lung adenocarcinoma (LUAD). However, the role of CDGs in LUAD prognosis has not been fully elucidated.

Methods: LUAD transcriptome data and CDG-related data were obtained from public databases and literature. Differentially expressed CDGs (DE-CDGs) greatly associated with LUAD survival (P < 0.05) were identified to establish a prognostic model. In addition, immune analysis of high-risk (HR) and low-risk (LR) groups was conducted by utilizing the CIBERSORT and single sample gene set enrichment analysis (ssGSEA) algorithms to assess immune differences. Subsequently, mutation analysis was conducted using maftools. Finally, candidate drugs were identified using the CellMiner database.

Results: 40 DE-CDGs significantly associated with LUAD survival and 11 DE-CDGs associated with prognosis were identified through screening. Regression analysis revealed that risk score can independently predict LUAD prognosis (P < 0.05). Immune landscape analysis revealed that compared to the HR group, the LR group had higher immune scores and high infiltration of various immune cells such as follicular helper B cells and T cells. Mutation landscape analysis demonstrated that missense mutation was the most common mutation type in both risk groups. Drug prediction analysis revealed strong correlations of fulvestrant, S-63845, sapacitabine, lomustine, BLU-667, SR16157, motesanib, AZD-9496, XK-469, dimethylfasudil, P-529, and imatinib with the model genes, suggesting their potential as candidate drugs targeting the model genes.

Conclusion: This study identified 11 effective biomarkers, DE-CDGs, which can predict LUAD prognosis and explored the biological significance of CDGs in LUAD prognosis, immunotherapy, and treatment.

References

Su L, Zhao J, Su H, Wang Y, Huang W, Jiang X . CircRNAs in Lung Adenocarcinoma: Diagnosis and Therapy. Curr Gene Ther. 2021; 22(1):15-22. DOI: 10.2174/1566523221666211202095258. View

Yang L, Wang S, Gerber D, Zhou Y, Xu F, Liu J . Main bronchus location is a predictor for metastasis and prognosis in lung adenocarcinoma: A large cohort analysis. Lung Cancer. 2018; 120:22-26. PMC: 7678407. DOI: 10.1016/j.lungcan.2018.03.011. View

Cronin K, Scott S, Firth A, Sung H, Henley S, Sherman R . Annual report to the nation on the status of cancer, part 1: National cancer statistics. Cancer. 2022; 128(24):4251-4284. PMC: 10092838. DOI: 10.1002/cncr.34479. View

Succony L, Rassl D, Barker A, McCaughan F, Rintoul R . Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies. Cancer Treat Rev. 2021; 99:102237. DOI: 10.1016/j.ctrv.2021.102237. View

Thammakumpee K . Clinical manifestation and survival of patients with non-small cell lung cancer. J Med Assoc Thai. 2004; 87(5):503-7. View

de Groot P, Munden R . Lung cancer epidemiology, risk factors, and prevention. Radiol Clin North Am. 2012; 50(5):863-76. DOI: 10.1016/j.rcl.2012.06.006. View

Biciusca V, Popescu I, Trasca D, Olteanu M, Stan I, Durand P . Diagnosis of lung cancer by flexible fiberoptic bronchoscopy: a descriptive study. Rom J Morphol Embryol. 2022; 63(2):369-381. PMC: 9804073. DOI: 10.47162/RJME.63.2.08. View

Grunnet M, Sorensen J . Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2011; 76(2):138-43. DOI: 10.1016/j.lungcan.2011.11.012. View

Mirka H, Ferda J, Krakorova G, Vodicka J, Mukensnabl P, Topolcan O . The Use of CT Pattern in Differentiating Non-invasive, Minimally Invasive and Invasive Variants of Lung Adenocarcinoma. Anticancer Res. 2021; 41(9):4479-4482. DOI: 10.21873/anticanres.15257. View

10.

Mzabi A, Benzarti W, Romdhane W, Baya W, Aissa S, Gargouri I . Erythema Nodosum Revealing Metastatic Lung Cancer. Eur J Case Rep Intern Med. 2021; 8(7):002539. PMC: 8336736. DOI: 10.12890/2021_002539. View

11.

Sun R, Hou Z, Zhang Y, Jiang B . Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma. Oncol Lett. 2022; 24(5):408. PMC: 9555020. DOI: 10.3892/ol.2022.13528. View

12.

Chandrashekar P, Ahmadinejad N, Wang J, Sekulic A, Egan J, Asmann Y . Somatic selection distinguishes oncogenes and tumor suppressor genes. Bioinformatics. 2020; 36(6):1712-1717. PMC: 7703750. DOI: 10.1093/bioinformatics/btz851. View

13.

Parsa N . Environmental factors inducing human cancers. Iran J Public Health. 2013; 41(11):1-9. PMC: 3521879. View

14.

Ghosh A, Stewart D, Matlashewski G . Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol. 2004; 24(18):7987-97. PMC: 515058. DOI: 10.1128/MCB.24.18.7987-7997.2004. View

15.

Mogi A, Kuwano H . TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol. 2011; 2011:583929. PMC: 3035360. DOI: 10.1155/2011/583929. View

16.

Harrison P, Vyse S, Huang P . Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2019; 61:167-179. PMC: 7083237. DOI: 10.1016/j.semcancer.2019.09.015. View

17.

Castellanos E, Feld E, Horn L . Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer. J Thorac Oncol. 2016; 12(4):612-623. DOI: 10.1016/j.jtho.2016.12.014. View

18.

Li B, Ross D, Aisner D, Chaft J, Hsu M, Kako S . HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. J Thorac Oncol. 2016; 11(3):414-9. PMC: 4698879. DOI: 10.1016/j.jtho.2015.10.025. View

19.

Bose R, Kavuri S, Searleman A, Shen W, Shen D, Koboldt D . Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2012; 3(2):224-37. PMC: 3570596. DOI: 10.1158/2159-8290.CD-12-0349. View

20.

Patelli G, Zeppellini A, Spina F, Righetti E, Stabile S, Amatu A . The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives. Cancer Treat Rev. 2022; 104:102351. DOI: 10.1016/j.ctrv.2022.102351. View